Tesamorelin and CJC-1295: A Comparison

Tesamorelin and CJC-1295 are both synthetic analogues of Growth Hormone-Releasing Hormone (GHRH), and they are often compared in research because they target the same axis through closely related sequences. This overview sets out what distinguishes the two.

What They Have in Common

Both Tesamorelin and CJC-1295 are GHRH analogues — synthetic compounds based on Growth Hormone-Releasing Hormone, the signalling peptide that prompts the pituitary to release growth hormone. Because they act on the same receptor, they are frequently studied side by side.

What Distinguishes Them

Tesamorelin is a stabilised GHRH analogue that has been the subject of clinical study. CJC-1295 is a separate GHRH analogue, more commonly handled as a research compound, and some versions carry a Drug Affinity Complex (DAC) modification that extends stability. The differences sit in their sequences and stability profiles.

How They Sit in Growth-Hormone Research

Both are studied within growth-hormone-axis research and are often examined alongside ghrelin-receptor secretagogues such as Ipamorelin, which act on a different point of the same axis.

Forms, Purity and Handling

• Format: lyophilised powder.

• Purity: greater than or equal to 99% by HPLC.

• COA: per batch.

• Storage: frozen for long-term stability; refrigerated once in solution.

Frequently Asked Questions

What do Tesamorelin and CJC-1295 have in common?

Both are synthetic analogues of Growth Hormone-Releasing Hormone (GHRH) and act on the same receptor.

How do they differ?

Tesamorelin is a stabilised GHRH analogue studied clinically; CJC-1295 is a separate analogue, often with a DAC modification, handled as a research compound.

What purity should they be?

Greater than or equal to 99% by HPLC with a per-batch COA.

These products are supplied strictly for laboratory and research use only. Not for human or animal consumption.